and large tumor suppressor 1/2) and a transcriptional module (e.g., yes-associated protein [YAP] and transcriptional co-activator with PDZ-binding motif [TAZ] ). In particular, the YAP-mediated gene transcriptional output is essential for hepatocellular carcinoma (HCC) initiation. Liver-specific YAP overexpression in transgenic mice leads to hepatomegaly and subsequent tumor formation. (4) (5) (6) Additionally, genetic knockdown of YAP reduces subcutaneous tumor growth of HCC lines. (7) The widespread expression and activation of YAP in human liver cancer further implicates YAP as an important HCC therapeutic target. (8) High mobility group protein B1 (HMGB1) belongs to a family of highly conserved chromosome proteins that contain HMG box domains. In addition to a nuclear function as a DNA chaperone, HMGB1 can be released into the extracellular environment and act as an immune mediator in infectious and sterile inflammation. Abnormal expression and release of HMGB1 are implicated in multiple human diseases. (9) HMGB1 has been reported to play dual roles in tumorigenesis depending on tumor type and its subcellular distribution. (10) Multiple clinical studies have shown that HMGB1 expression and release is increased in human HCC. (11) Extracellular HMGB1 promotes the growth, migration, and metastasis of HCC cells, (12) whereas intracellular HMGB1 mediates mitochondrial biogenesis in liver tumor growth. (13) However, the specific role of intracellular HMGB1 in metabolic reprogramming during liver tumorigenesis remains largely unknown.
In the current study, we provide transgenic animal evidence that intracellular HMGB1 plays an oncogenic role in primary liver cancer. We observed that conditional knockout of HMGB1 in hepatocytes delayed diethylnitrosamine (DEN)-induced liver cancer initiation in mice. Mechanistically, we demonstrated that HMGB1 is a regulator of the Hippo pathway and that HMGB1-mediated YAP expression contributes to aerobic glycolysis in tumor growth. Our data therefore identify a key role for HMGB1 action in the modulation of the Hippo pathway and metabolic reprogramming in liver tumorigenesis. Thus, targeting this HMGB1-YAP-dependent metabolic pathway holds promise as a novel anticancer strategy.
Materials and Methods

ANTIBODIES AND REAGENTS
The antibodies to HMGB1 (#3935), YAP (#14074), TAZ (#4883), Axin1 (#2087), b-catenin (#9587), Notch1 (#3608), Notch2 (#5732), histone deacetylase 2 (#5113), proliferating cell nuclear antigen (#2586), cyclin D1 (CCND1; #2922), cleaved-caspase 3 (#9661), the histone gamma-H2AX (#9718), glyceraldehyde 3-phosphate dehydrogenase (#2118), and actin (#3700) were obtained from Cell Signaling Technology. The antibody to GA-binding protein a (GABPa; #21542-1-AP) was obtained from Proteintech Group. The antibody to p73 (#ab26123) was obtained from Abcam. The antibody to hypoxia-inducible factor 1a (HIF1a; #NB100-105) was obtained from NOVUS. DEN (#N0258), glycyrrhizin (#CDS020796), verteporfin (#SML0534), glucose (#G8270), oligomycin (#O4876), and 2-deoxy-D-glucose (2-DG; #D8375) were obtained from Sigma.
CELL LINES AND CULTURE
Hepa1-6, HepaG2, and Hep3B cells were obtained from the American Type Culture Collection. HuH7 cells were a gift from Dr. Allan Tsung. HMGB1 -/-mouse embryonic fibroblasts (MEFs) were a gift from Dr. Marco E. Bianchi. These cells were grown in Eagle's minimum essential medium (HepaG2 and Hep3B) or Dulbecco's modified Eagle's medium (Hepa1-6, HuH7, and MEFs) with 10% fetal bovine serum, 2 mM L-glutamine, and 100 U/mL penicillin and streptomycin.
HEPATOCYTE ISOLATION
Hepatocytes were isolated from tissue samples taken from HCC patients who had undergone hepatic resections or from livers of mice. Sample collection from patients was approved by the Institutional Review Board. Hepatocyte isolation was carried out using a modified two-stage collagenase procedure developed by Berry and Friend. (14) CELL VIABILITY AND CLONOGENIC CELL SURVIVAL ASSAY Cell viability was assayed using Cell Counting Kit-8 kits (Dojindo Laboratories). Long-term cell survival was monitored in a colony formation assay. In brief, 1,000 cells were reseeded into 24-well plates after treatment with indicated drugs for 24 hours. The cells were allowed to grow for the next 10 to 12 days to allow colony formation. The colonies were visualized using crystal violet staining.
WESTERN BLOT ANALYSIS
Western blot was used to analyze protein expression as described. (15) In brief, after extraction, proteins in the cell lysate were resolved on 4%-12% Criterion XT Bis-Tris gels (Bio-Rad) and transferred to a nitrocellulose membrane. After blocking with 5% milk, membranes were incubated for 2 hours at 258C with various primary antibodies. After incubation with peroxidaseconjugated secondary antibodies for 1 hour at room temperature, the signals were visualized using enhanced or super-chemiluminescence and exposure to x-ray films.
IMMUNOPRECIPITATION ANALYSIS
Cells were lysed at 48C in ice-cold radioimmunoprecipitation assay buffer, and cell lysates were cleared using brief centrifugation. Concentrations of proteins in the supernatant were determined using the bicinchoninic acid assay. Prior to immunoprecipitation, samples containing equal amounts of proteins were precleared with protein G agarose (48C, 3 hours) and subsequently incubated with various irrelevant immunoglobulin G or specific antibodies (2-4 mg/mL) in the presence of protein G agarose beads overnight at 48C with gentle shaking. Following incubation, agarose beads were washed extensively with phosphatebuffered saline (PBS) and proteins were eluted by boiling in 2X sodium dodecyl sulfate sample buffer before sodium dodecyl sulfate polyacrylamide gel electrophoresis.
RNA INTERFERENCE AND GENE TRANSFECTION
The human HMGB1-short hairpin RNA (shRNA)-1 ( and 5 0 -TTTTTCGTCACTACCTCCCCG-3 0 ), using a CFX96 Touch Real-Time PCR Detection System (Bio-Rad) with SsoFast EvaGreen Supermix (#1725201; Bio-Rad). The 18S rRNA was used to normalize the relative expression levels of target genes.
GLYCOLYSIS ASSAY
Cellular glycolysis was monitored using the Seahorse Bioscience Extracellular Flux Analyzer (XF24; Seahorse Bioscience Inc., North Billerica, MA) by measuring the extracellular acidification rate (ECAR) in real time as described. (16, 17) SERUM BIOCHEMISTRY Serum levels of lactate (#MAK064; Sigma), glucagon (#RAB0202; Sigma), and insulin (#EMINS; Thermo Fisher Scientific Inc.) were measured using enzyme-linked immunosorbent assay (ELISA) per the manufacturer's protocol. For measurement of serum nucleosomes, Cell Death Detection ELISA plus (#11920685001; Roche Diagnostics) was used. Glucose concentration measurements were obtained from whole-blood samples using hand-held whole-blood glucose monitors (Bayer) according to the manufacturer's protocol.
HIF1a ACTIVATION ASSAY
HIF-1a Transcription Factor Assay (#ab133104; Abcam) is a nonradioactive sensitive method for detecting HIF1a DNA binding activity to core DNA sequence 5'-[AG]CGTG-3' within the hypoxia response element of target gene promoters in nuclear extracts or whole cell lysate per the manufacturer's instructions. HIF1a luciferase reporter activity was assayed using Cignal HIF Reporter Kits (#CCS-007L; QIAGEN) according to the manufacturer's protocol.
SECRETE-PAIR LUMINESCENCE ASSAY
Cells were transfected with pEZX-PG04-YAPpromoter-Gaussia luciferase/secreted alkaline phosphatase (#MPRM35478-PG04; GeneCopoeia). YAP promoter luciferase activity was measured using a secrete-pair dual luminescence assay kit (#SPDA-D010; GeneCopoeia) in accordance with the manufacturer's guidelines.
CHROMATIN IMMUNOPRECIPITATION ASSAY
The chromatin immunoprecipitation assay (ChIP) was performed according to the protocol of the ChIP kit (#17-295; EMD Millipore) as described. (18) Briefly, cells were fixed with 1% formaldehyde for 10 minutes at room temperature and then quenched with glycine for 5 minutes. The fixed cells were washed with PBS containing protease inhibitors and lysed in lysis buffer for 10 minutes on ice prior to sonication, centrifugation, and addition of dilution buffer. One percent of input was removed, and the lysates were immunoprecipitated with 2 mg of anti-GABPa antibody, anti-HMGB1 antibody, or control immunoglobulin G for 2 hours. Salmon sperm DNA/protein A/G-Sepharose beads were added to these immunoprecipitations for incubation overnight. Immune complex pellets were washed and then eluted. The elutes were heated at 658C for 4 hours to reverse the crosslinking and treated with RNase A for 30 minutes at 378C, followed by treatment with proteinase K for 1 hour at 458C to remove RNA and protein. DNA was recovered, eluted, and then assayed using PCR.
ANIMALS AND TREATMENTS
All animal experiments were approved by the Institutional Animal Care and Use Committees. Hepa1-6 or HuH7 cells in 100 lL PBS were injected subcutaneously to the right of the dorsal midline in 6-8-week-old athymic nude or B6 mice. Once the tumors reached 50-70 mm 3 at day 7, mice were randomly allocated into groups and treated with glycyrrhizin (50 or 100 mg/kg, intraperitoneally) or verteporfin (25 or 50 mg/kg, intraperitoneally) every day beginning day 7 postxenograft injection for 2 weeks. Tumors were measured twice weekly, and volumes were calculated using the formula length 3 width (2) 3 p/6. To generate DEN-induced liver tumors, 15-day-old male mice were treated with a single intraperitoneal injection of DEN (5 mg/kg body weight). Mice were then randomly allocated into groups and treated with glycyrrhizin (100 mg/kg, intraperitoneally) or verteporfin (50 mg/kg, intraperitoneally) twice every week for 2 months. Liver tissues were harvested to determine messenger RNA (mRNA) and protein levels at 3, 5, or 10 months after DEN-induced tumorigenesis. Tumors were counted and measured externally and internally using a combination of visual inspection and hematoxylin and eosin staining as described. (19) 
STATISTICAL ANALYSIS
Unless otherwise indicated, data are expressed as means 6 SD. Unpaired Student t tests were used to compare the means of two groups. One-way analysis of variance was used for comparison among the different groups. When the analysis of variance was significant, post-hoc testing of differences between groups was performed using the least significant difference test. Differences with P < 0.05 were considered statistically significant.
Results
HMGB1 DELETION INHIBITS LIVER CANCER INITIATION
To determine the role of HMGB1 in tumorigenesis, we first analyzed the expression of HMGB1 in the liver after male B6 mice were challenged with DEN. Q-PCR and western blot analysis showed that the hepatic expression levels of HMGB1 mRNA (Fig. 1A) and protein (Fig. 1B,C) were initially upregulated at 3 and 5 months and then restored to basal expression levels at 10 months after DEN treatment, suggesting that HMGB1 may play a different role in liver cancer initiation, progression, and advancement.
To define the time frame at which HMGB1 is required for liver tumor development, hepatocytespecific HMGB1 knockout mice (Hmgb1 -/-mice) were used. HMGB1 protein expression was constitutively deleted in hepatocytes of Hmgb1 -/-mice compared to control Hmgb1 f/f mice (Fig. 1D) . In contrast, HMGB1 protein expression in the kidney and lung did not differ between the Hmgb1 -/-and Hmgb1 f/f mice (Fig. 1D) . Notably, the rate of liver tumorigenesis was significantly reduced by HMGB1 deletion at 3 and 5 months but not at 10 months after DEN treatment (Fig. 1E) . Consistently, the number ( 
HMGB1 REGULATES THE HIPPO PATHWAY
We recently demonstrated that intracellular HMGB1 inhibits pancreatic tumorigenesis partly through blocking DNA damage-mediated proinflammatory nucleosome release. (20) Interestingly, the levels of cH2AX (a marker of DNA damage) and cleaved caspase-3, a marker of cell apoptosis, in livers ( Fig.  2A,B ) and circulating nucleosome (Fig. 2C) were not affected by hepatic HMGB1 depletion at 3 or 5 months after DEN treatment. In contrast, the expression levels of cell proliferation markers, such as proliferating cell nuclear antigen and CCND1, were significantly reduced in livers from Hmgb1 -/-mice following DEN treatment ( Fig. 2A,B ). These results demonstrate that HMGB1 is required for cell proliferation but not cell death or DNA damage during liver cancer initiation.
To search for downstream cell proliferation effectors of HMGB1-mediated liver cancer initiation, we examined the expression levels of several signaling molecules (e.g., Wnt/b-catenin, Notch, and Hippo) implicated in the regulation of cell proliferation during liver carcinogenesis. Q-PCR (Fig. 2D ) and western blot (Fig.  2E,F) analysis confirmed that the expression of core components of the Hippo pathway (e.g., YAP and TAZ) was reduced in livers of DEN-induced Hmgb1 -/-mice. In contrast, the expression of core components of the Wnt/b-catenin (e.g., b-catenin and Axin1) and Notch pathways (e.g., Notch1 and Notch2) was not affected by HMGB1 depletion during DEN-induced liver tumorigenesis (Fig. 2D-F) .
Given that GABPa is an important transcription regulator of YAP gene expression, (18) we hypothesized that HMGB1 can bind GABPa to regulate YAP promoter activity. Indeed, a direct interaction between HMGB1 and GABPa occurred in liver extracts after DEN treatment (Fig. 2G) . The ChIP assay showed that GABPa and HMGB1 bond to the YAP promoter in primary mouse hepatocytes (Fig. 2H) . As expected, loss of HMGB1 in hepatocytes significantly inhibited YAP promoter activity (Fig. 2I) . Like HMGB1, the hepatic expression levels of YAP protein were initially up-regulated at 3 and 5 months and were then restored to basal expression levels at 10 months after DEN treatment (Fig. 2J) .
To better understand the role of HMGB1 in the regulation of the Hippo pathway, we further measured the mRNA expression levels of YAP target genes, such as BIRC5, CCND1, MYC, SPP1, and GPC3. The expressions of these target genes were all down- regulated in the livers of Hmgb1 -/-mice after DEN treatment (Fig. 2D) , supporting HMGB1 as a regulator of the Hippo pathway.
In addition to acting as an oncogene in many cases, YAP may occasionally serve as a tumor suppressor through a complex interaction with other transcription factors.
(2,(3)) For example, YAP binds to tumor suppressor p73, contributing to the transcription of proapoptotic genes (e.g., BAX and PUMA) in several hematologic cancers. (21) However, the YAP-p73 complex was not observed in DEN-induced liver tumorigenesis (Fig. 2K) . Additionally, mRNA of BAX and PUMA was not affected by HMGB1 in DENinduced liver tumorigenesis (Fig. 2D) .
YAP IS RESPONSIBLE FOR HMGB1-MEDIATED CELL GROWTH
We next examined whether genetic inhibition of HMGB1 affected YAP expression in HCC cells. Knockdown of HMGB1 by two specific shRNAs reduced mRNA expressions of YAP and its target genes (BIRC5, CCND1, MYC, and SPP1) in Hepa1-6 and HuH7 cells (Fig. 3A) . Consistently, knockdown of HMGB1 also decreased YAP protein expression (Fig. 3B) . In contrast, genetic silencing of YAP did not affect HMGB1 expression, suggesting that HMGB1 expression is not reversely regulated by YAP (Fig. 3C) . In addition to HCC cell lines, we also observed that the protein expression of YAP was diminished in HMGB1 -/-MEF cell lines (Fig. 3D) . Enforced genetic expression of HMGB1-cDNA restored expression of HMGB1 as well as YAP in HMGB1 -/-MEFs (Fig. 3D) . However, the enforced expression of YAPcDNA restored YAP expression but not HMGB1 expression in HMGB1-knockdown HCC cells (Fig.   3E ). These results clearly indicate that YAP expression is controlled by HMGB1 but not vice versa.
We next analyzed whether YAP expression is responsible for HMGB1 function in cell survival and proliferation. The direct knockdown of YAP by shRNA recapitulates the HMGB1-deficient phenotype in cell proliferation (Fig. 3F) and colony formation (Fig. 3G,H) . Conversely, the enforced expression of YAP reversed these phenotypes in HMGB1-knockdown cells (Fig. 3F-H) . These findings suggest that YAP expression is responsible for HMGB1 function in cell proliferation and growth.
HMGB1-YAP PATHWAY MEDIATES THE WARBURG EFFECT
The Warburg effect, also known as aerobic glycolysis, is a metabolic hallmark of most cancer cells, including HCC, characterized by an excessive conversion of glucose to lactate, even with ample oxygen. To assess whether the HMGB1-YAP pathway is responsible for the Warburg effect in liver tumorigenesis, we first measured serum levels of lactate, glucose, insulin, and glucagon in Hmgb1 f/f and Hmgb1 -/-mice after treatment with DEN. The level of lactate was significantly down-regulated in Hmgb1 -/-mice compared with Hmgb1 f/f following DEN treatment at 3 and 5 months (Fig. 4A) . In contrast, serum levels of glucose (Fig. 4B), insulin (Fig. 4C) , and glucagon (Fig. 4D) did not differ between DEN-induced Hmgb1 -/-and Hmgb1 f/f mice. Thus, HMGB1 is required for lactate production but not glucose production during DEN-induced liver tumorigenesis.
To further define the role of HMGB1 in the regulation of lactate production, we measured ECAR in hepatocytes using the Seahorse Bioscience Extracellular Flux Analyzer. This assay was started in the absence of glucose; then glucose, oligomycin, and 2-DG were sequentially added as described. (17) The level of aerobic glycolysis was significantly reduced in hepatocytes derived from Hmgb1 -/-mice compared to hepatocytes from Hmgb1 f/f mice (Fig. 4E) . Genetic inhibition of HMGB1 or YAP by shRNA in Hepa1-6 (Fig. 4F) and HuH7 (Fig. 4G ) cells also resulted in a decrease in ECAR. In contrast, the enforced expression of YAP or HMGB1 restored ECAR in HMGB1-knockdown cells (Fig. 4F,G) . The enforced expression of YAP also restored ECAR in YAP-knockdown cells (Fig. 4F,G) . 
FIG. 5
These findings support our hypothesis that HMGB1-mediated YAP expression contributes to aerobic glycolysis in HCC cells.
Compared with normal cells, glycolysis is accelerated in HCC cells by preferential expression of glucose transporters (e.g., GLUT1) and enzyme isoforms (e.g., HK2, ALDOA, and LDHA) that drive glucose flux forward and to adapt to the anabolic demands of cancer cells. (22) We therefore explored whether the HMGB1-YAP pathway regulates glycolysis through targeting these glycolysis-associated genes. Indeed, the mRNA levels of GLUT1, HK2, ALDOA, and LDHA were all down-regulated in the livers of Hmgb1 -/-mice during DEN-induced tumorigenesis (Fig. 4H) . The knockdown of HMGB1 or YAP in HCC cells also led to down-regulation of glycolysisassociated genes (GLUT1, HK2, ALDOA, and LDHA) and YAP-targeted genes (BIRC5, CCND1, SPP1, and GPC3) (Fig. 4I) . Like the enforced expression of YAP or HMGB1 in HMGB1-knockdown cells, the enforced expression of YAP also restored expression of these genes in YAP-knockdown HCC cells (Fig. 4I) . Collectively, the changes in expression of genes involved in glycolysis could inform the underlying biological mechanisms by which HMGB1 and YAP contribute to DEN-induced liver tumorigenesis.
INTERPLAY BETWEEN HMGB1, YAP, AND HIF1a CONTRIBUTES TO LIVER TUMORIGENESIS
HIF1a is implicated in modulating key enzymes involved in aerobic glycolysis as well as key processes required for the Warburg effect. HIF1a DNA binding activity in hepatocytes was decreased in Hmgb1 -/-mice following DEN treatment (Fig. 5A) . Knockdown of HMGB1 or YAP in HCC cells also decreased HIF1a DNA binding activity and luciferase reporter activity with or without hypoxia (Fig. 5B) . In contrast, the enforced expression of YAP or HMGB1 restored HIF1a DNA binding activity and luciferase reporter activity in HMGB1-knockdown cells (Fig. 5B) . Consistently, hypoxia-induced expression of GLUT1, HK2, ALDOA, and LDHA as well as carbonic anhydrase 9 (a well-known HIF1a-targeted gene), were inhibited in HMGB1-or YAP-knockdown cells (Fig. 5C) .
We next determined whether the HMGB1-YAP pathway regulates HIF1a activity through modulating its expression and degradation. The protein level of HIF1a was not significantly affected by the depletion of HMGB1 or YAP in hepatocytes (Fig. 5D ) or Hepa1-6 cells (Fig. 5E ). In contrast, the DEN-or hypoxiainduced interaction between YAP and HIF1a was decreased in hepatocytes from Hmgb1 -/-mice (Fig. 5D ) or HMGB1/YAP-knockdown cells (Fig. 5E ). YAPHIF1a complex formation was observed in the nucleus but not in the cytosolic extract of hepatocytes from DEN-induced Hmgb1 f/f mice (Fig. 5F ). These findings, therefore, indicate that HMGB1-mediated YAP upregulation contributes to HIF1a activation through formation of the nuclear YAP-HIF1a complex.
To elucidate the possible role of HIF1a in the regulation of the Warburg effect in liver tumorigenesis, we tested whether HIF1a depletion impairs lactate production and mRNA expression of aerobic glycolysis genes in vivo. Conditional knockout of HIF1a (termed Hif1a -/-) in mice liver inhibited DENinduced liver tumor imitation (Fig. 5G) . Consistently, the number (Fig. 5H)/size (Fig. 5I) of HCC nodules and liver weight (Fig. 5J) were reduced in DEN-induced Hif1a -/-mice, supporting the notion that a hypoxic microenvironment promotes tumor growth. This process was also associated with decreased serum lactate (Fig. 5K ) and mRNA expression of GLUT1, HK2, ALDOA, and LDHA in livers from DEN-induced Hif1a -/-mice (Fig. 5L) . Interestingly, the mRNA expression of HMGB1, YAP, and YAP-targeted genes (BIRC5, CCND1, SPP1, and GPC3) also decreased in livers from DEN-induced Hif1a -/-mice (Fig. 5L) , suggesting a possible feedback loop between the expression of these genes in metabolic reprogramming.
A recent study showed that HMGB1-mediated pPGC1a expression contributes to hypoxia-mediated mitochondrial biogenesis in HCC cells. (13) Knockdown of PGC1a caused mild down-regulation of ECAR compared to knockdown of HMGB1 in Hepa1-6 cells (Fig. 5M,N) . However, forced expression of PGC1a cDNA did not rescue ECAR in HMGB1-knockdown cells (Fig. 5M,N) . Thus, in the absence of HMGB1, PGC1a was not sufficient to increase glycolysis in HCC cells.
We next knocked down GLUT1 and HK2 by shRNA in Hepa1-6 and HuH7 cells (Fig. 5O) . Suppression of GLUT1 and HK2 expression significantly inhibited cell proliferation (Fig. 5P) , indicating that aerobic glycolysis contributes to HCC cell growth.
PHARMACOLOGIC INHIBITION OF THE HMGB1-YAP PATHWAY LIMITS LIVER TUMOR CELL GROWTH IN VITRO
Glycyrrhizin, a direct HMGB1 inhibitor, has been demonstrated as a promising anticancer agent for the treatment of several solid cancers. (23) Verteporfin, a U.S. Food and Drug Administration-approved drug currently used to treat neovascular macular degeneration, has the ability to block YAP activity to inhibit the growth of breast, pancreas, and colon cancers. (24) However, anticancer activity and the mechanism of action of glycyrrhizin and verteporfin in HCC remain obscure.
Thus, we employed four different murine and human HCC cell lines (Hepa1-6, HuH7, HepG2, and Hep3B) and primary human HCC cells, to elucidate the tumor suppression mechanisms of glycyrrhizin and verteporfin. First, treatment with glycyrrhizin or verteporfin limited cell proliferation (Fig. 6A ) and colony formation (Fig. 6B ) in these cells. Second, glycyrrhizin or verteporfin suppressed the mRNA expression levels of glycolysis-associated genes (GLUT1, HK2, ALDOA, and LDHA) (Fig. 6C) . Third, ECAR levels were decreased in Hepa1-6 (Fig. 6D) , HuH7 (Fig.  6E) , and primary human HCC (Fig. 6F ) cells after treatment with glycyrrhizin or verteporfin. Finally, glycyrrhizin or verteporfin remarkably inhibited HIF1a DNA binding activity (Fig. 6G ) and HIF1a-YAP complex formation (Fig. 6H) . These findings support our hypothesis that the HMGB1-YAP pathway promotes tumor growth in HCC cells through activation of HIF1a-dependent aerobic glycolysis.
Given that verteporfin can inhibit YAP activity through blocking YAP-TEA domain transcription factor (TEAD) interaction, (24) we next determined the effects of TEAD on the YAP-HIF1a complex. The YAP-5SA-S94A mutant selectively abolishes YAP's ability to bind TEAD but does not impair its general transcriptional activity. (25) Like wild-type YAPcDNA, YAP-5SA-S94A was still able to restore HIF1a DNA binding activity (Fig. 6I) , glycolysisassociated gene (GLUT1, HK2, ALDOA, and LDHA) expression (Fig. 6J) , and HIF1a-YAP complex formation (Fig. 6K ) in YAP-knockdown HuH7 cells with or without hypoxia. 
PHARMACOLOGIC INHIBITION OF THE HMGB1-YAP PATHWAY PREVENTS TUMOR GROWTH IN VIVO
To evaluate the anticancer activity of glycyrrhizin and verteporfin in vivo, human HuH7 cells or mouse Hepa1-6 cells were implanted into the subcutaneous space of the right flank of immunodeficient nu/nu mice or immunocompetent B6 mice, respectively. Beginning on day 7 posttumor implantation, mice were administered glycyrrhizin (50 and 100 mg/kg, intraperitoneally) or verteporfin (25 and 50 mg/kg, intraperitoneally) for 2 weeks. Compared to the vehicle control group, administration of glycyrrhizin or verteporfin effectively reduced tumor growth (Fig. 7A) as it decreased serum lactate levels ( Fig. 7B ) and mRNA expression of GLUT1, HK2, ALDOA, and LDHA (Fig. 7C ) in the tumor.
We next evaluated the anticancer activity of glycyrrhizin and verteporfin in DEN-induced liver tumorigenesis. Administration of glycyrrhizin (100 mg/kg, intraperitoneally) and verteporfin (50 mg/kg, intraperitoneally) inhibited DEN-induced liver tumor imitation (Fig. 7D) . Consistently, the number (Fig. 7E)/size (Fig.  7F ) of HCC nodules and liver weight (Fig. 7G) were reduced after glycyrrhizin or verteporfin treatment. This process was also associated with decreased serum lactate (Fig. 7H) as well as mRNA expression of GLUT1, HK2, ALDOA, and LDHA in livers (Fig. 7I) . These results further support the notion that pharmacologic inhibition of the HMGB1-YAP pathway prevents liver tumor growth through inhibition of aerobic glycolysis.
Discussion
Tumorigenesis has been recognized as not only a process intrinsic to genetic instability but also a consequence of metabolic reprogramming. Here, we identified an HMGB1-dependent regulatory network involving YAP and HIF1a that controls metabolic reprogramming during liver cancer initiation (Fig. 7J) . Targeting either HMGB1 or YAP by glycyrrhizin or verteporfin effectively prevented the proliferation of initiated tumor cells and tumorigenesis, providing a potential strategy for HCC prevention.
While most studies investigating the action of HMGB1 in tumorigenesis have focused on its DNA repair and proinflammatory activity capabilities, (26) HMGB1 also plays metabolic roles involved in the regulation of autophagy that may contribute to drug resistance. (15) Macrophages can release HMGB1 to trigger an inflammatory response in an aerobic glycolysis-dependent manner. (27) In addition, HMGB1 released from cancer cells induces autophagy in the muscle, which mediates the Warburg effect during tumor growth in vitro and in vivo. (28) However, extracellular HMGB1 also has the ability to induce cell death through limiting the Warburg effect in clone cancer cells. (29) This dual activity of extracellular HMGB1 in the regulation of the Warburg effect may depend on its redox status, cleavage, and receptors.
HMGB1 has also been shown to interact with and modulate the activities of a number of transcription factors (e.g., p53 and estrogen receptor) implicated in tumor development. (10) These functions of HMGB1 are mediated by its ability to bind and bend to DNA in a nonsequence-specific manner. We show here that HMGB1 can bind GABPa to activate YAP transcription in hepatocytes. The GABP transcription factor has been linked to the regulation of diverse genes, including YAP, in the Hippo pathway. (18) Our findings are consistent with other studies emphasizing the importance of HMGB1 in the regulation of GABP transcription factor activity in cancer cells. 6 cells/mouse) or HuH7 cells (2 3 10 6 cells/mouse) and treated with glycyrrhizin (50 or 100 mg/kg, intraperitoneally every other day) or verteporfin (25 or 50 mg/kg, intraperitoneally every other day) at day 7 for 2 weeks. Tumor volume was calculated twice weekly. Data is expressed as means 6 SD (n 5 10 mice/group; *P < 0.05). (B) Analysis of serum lactate levels in mice at day 28 after treatment. Data are presented as median value (black line), interquartile range (box), and minimum and maximum of all data (black line) (n 5 10 mice/group; *P < 0.05). (C) Q-PCR analysis of mRNA expressions of indicated genes in livers at day 28 (n 5 3 mice/group; *P < 0.05). (D) Percentage of DEN-induced liver tumors in mice after treatment with glycyrrhizin (100 mg/kg, intraperitoneally twice every week for 2 months) or verteporfin (50 mg/kg, intraperitoneally twice every week for 2 months) at 3-5 months of age (n 5 10 for each group; *P < 0.05). (E) Number and (F) size of HCC nodules and (G) liver weight in indicated mice (n 5 10 for each group; *P < 0.05). In this study, we demonstrated that HMGB1-mediated YAP expression contributes to metabolic reprogramming in liver tumorigenesis. In the initiated liver cancer cells, the expression of YAP is controlled by HMGB1. Disruption of the YAP gene in HCC cells with wild-type HMGB1 recapitulates growth inhibition, deficits in aerobic glycolysis, and lactate production observed with targeted deletion of HMGB1. Forced expression of YAP reverses this phenotype in HMGB1-silencing cells. The Warburg effect mediated by HMGB1 regulation of YAP expression may serve as a metabolic checkpoint, enabling cell proliferation in the hypoxic tumor microenvironment. While increased nucleosome release was observed in HMGB1-deficient pancreas following KRas stress, (20) circulating nucleosome levels were unchanged in HMGB1-deficient livers following DEN treatment. This may explain the unchanged overall DNA damage and cell death observed in DEN-treated HMGB1-deficient livers compared to HMGB1-wild-type livers.
Functionally, our study indicated that the HMGB1-YAP pathway is required for HIF1a transcriptional activity but not HIF1a expression. We also showed that the formation of the YAP-HIF1a complex was not affected by the YAP-5SA-S94A mutant. In contrast, verteporfin, a well-known reagent targeting the interface between YAP and TEAD, (24) still had the ability to block YAP-HIF1a complex formation. These findings indicate that HMGB1 regulates YAP, which then regulates transcription with TEAD factors, and that all the data on HIF1a are either something happening in parallel or downstream of the YAP-TEAD complex. Of note, verteporfin can inhibit YAP function through up-regulating 14-3-3r, which is TEAD independent. (31) The precise role of TEAD in the regulation of HIF1a activity remains to be further explored.
HIF1a is found to be expressed at higher levels in dysplastic nodules and implicated in the progression of hepatocarcinogenesis.
(32) Consistently, we found that knockout of HIF1a inhibited DEN-induced tumor formation associated with decreased lactate production in mice. The HIF1a-mediated Warburg effect not only supports tumor cell growth but also limits antitumor T-cell responses. (33) The present study suggests a link between YAP and HIF1a in liver cancer initiation. YAP binds HIF1a in the nucleus to activate the transcription of glycolysis genes, which in turn mediates the Warburg effect to acquire necessary energy to support proliferation. Our animal study also shows that activation of HIF1a is required for HMGB1 and YAP expression in hepatocytes. Further evidence is needed to determine whether functional crosstalk occurs between both cascades as a metabolism-induced feedback loop in HCC.
